Neurocrine Biosciences announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1065890 in healthy adult participants. NBI-1065890 is an investigational, oral, selective inhibitor of the vesicular monoamine transporter-2 for the potential treatment of certain neurological and neuropsychiatric conditions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $158 from $148 at JPMorgan
- Spruce Biosciences downgraded to Market Perform from Outperform at Leerink
- Neurocrine price target raised to $200 from $170 at Oppenheimer
- Voyager Therapeutics reports selection of gene therapy development candidate
- JPMorgan biotech analysts to hold an analyst/industry conference call
